The immunotherapy agent pembrolizumab, has been approved by the FDA to treat PD-L1-positive metastatic EAC and ESCC in July 2019, but patients contained PD-L1 expression is not so high to response to this agent (Barsouk et al., 2019). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.